免疫疗法
癌症研究
药代动力学
正电子发射断层摄影术
肿瘤微环境
医学
药理学
小分子
免疫系统
肿瘤细胞
化学
免疫学
核医学
生物化学
作者
Noor Momin,Joseph R. Palmeri,Emi A. Lutz,Noor Jailkhani,Howard H. Mak,Anthony Tabet,Magnolia M. Chinn,Byong H. Kang,Virginia Spanoudaki,Richard O. Hynes,K. Dane Wittrup
标识
DOI:10.1038/s41467-021-27390-6
摘要
Abstract Direct injection of therapies into tumors has emerged as an administration route capable of achieving high local drug exposure and strong anti-tumor response. A diverse array of immune agonists ranging in size and target are under development as local immunotherapies. However, due to the relatively recent adoption of intratumoral administration, the pharmacokinetics of locally-injected biologics remains poorly defined, limiting rational design of tumor-localized immunotherapies. Here we define a pharmacokinetic framework for biologics injected intratumorally that can predict tumor exposure and effectiveness. We find empirically and computationally that extending the tumor exposure of locally-injected interleukin-2 by increasing molecular size and/or improving matrix-targeting affinity improves therapeutic efficacy in mice. By tracking the distribution of intratumorally-injected proteins using positron emission tomography, we observe size-dependent enhancement in tumor exposure occurs by slowing the rate of diffusive escape from the tumor and by increasing partitioning to an apparent viscous region of the tumor. In elucidating how molecular weight and matrix binding interplay to determine tumor exposure, our model can aid in the design of intratumoral therapies to exert maximal therapeutic effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI